Navigation Links
Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
Date:5/7/2009

MACCLESFIELD, England, May 7 /PRNewswire-FirstCall/ -- Cyprotex today (7th May 2009) launches Cloe(R) Gateway, a new secure web portal for access to drug discovery services. The initial offering via Cloe(R) Gateway is a new enhanced version of our proprietary predictive software, Cloe(R) PK, which predicts whole body pharmacokinetics from simple in vitro ADME and physicochemical properties.

Commenting on the launch, Dr Anthony D. Baxter, Cyprotex's Chief Executive Officer, said:

"I am delighted to announce the launch of our new and novel web portal Cloe(R) Gateway and its first product, an improved version of Cloe(R) PK. Cloe(R) PK, as a server based product, has been used by many of our customers for prediction of pharmacokinetic properties from early ADME data and found it to be very useful in decision making for candidate selection. Cyprotex have invested considerable time and effort improving the Cloe(R) PK model and we are proud to launch version 2.1 as an online service available via Cloe(R) Gateway. This will enable many more of our customers to utilise this excellent product on a simple pay-per-use model. The cost effectiveness of this approach will allow access of such predictive technologies to new audiences of scientists such as bench medicinal chemists. This approach to selling software solutions is new to the ADME / pharmacokinetic world and we anticipate it will grow to replace competitor products still being sold on the outdated server / license model.

The pharmaceutical industry has amassed a huge quantity of ADME data over the past few years and the availability of an online version of Cloe(R) PK though Cloe(R) Gateway will enable those companies to realise tremendous real added value from that data in the form of pharmacokinetic performance characteristics to enable faster, cheaper and better designed drugs to be developed.

I look forward to announcing further new products to be sold through Cloe(R) Gateway such as a human intestinal absorption model and a product to enable customers to access our largest selling product Cloe(R) Screen in the near future."

    For further information:
    Cyprotex PLC
    Helen Gill PhD, Product Development Manager
    Tel: +44(0)1625-505-100
    h.gill@cyprotex.com
   http://www.cyprotex.com


'/>"/>
SOURCE Cyprotex Discovery Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
2. Cyprotex Introduces New Product Line Cloe(R) Select - a Portfolio of Bespoke ADME and PK Services
3. Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tephas Proprietary Biomaterial
4. Elsevier Launches Ten New eBook Specialty Collections on MD Consult
5. Histogen Aesthetics Launches ReGenica Rejuvenation System
6. AMG Launches EVOS fl, an 'Evolutionary' Fluorescence Microscope Based on Innovative EVOS Platform
7. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
8. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
9. Cell Biosciences Launches Next-Generation Protein Characterization System
10. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
11. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... , ... October 10, 2017 , ... Dr. Bob Harman, ... his local San Diego Rotary Club. The event entitled “Stem Cells ... and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):